TScan Therapeutics, Inc. (TCRX) Earnings
TScan Therapeutics, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Next earnings (estimated)
Around Nov 11, 2026
From past filing pattern
Get notified when TCRX reports →Last reported earnings
Aug 12, 2026
From the latest earnings 8-K
Revenue • FY2025
$10.32M
▲ 266.7%YoY
Diluted EPS • FY2025
$-1.00
▲ 12.3%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from TCRX's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $10.32M | -$129.77M | — | $-1.00 | -$139.73M | -1315.4% | +266.7% |
| FY2024 | $2.82M | -$127.5M | — | $-1.14 | -$114.65M | -4787.7% | -86.6% |
| FY2023 | $21.05M | -$89.22M | — | $-1.36 | -$64.5M | -444.0% | +55.5% |
| FY2022 | $13.54M | -$66.22M | — | $-2.75 | -$70.73M | -492.3% | +33.5% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 12, 2026 | 8-K (2.02) | 0001193125-26-345732EDGAR |
| May 6, 2026 | 8-K (2.02) | 0001193125-26-207549EDGAR |
| Mar 4, 2026 | 8-K (2.02) | 0001193125-26-089871EDGAR |
| Nov 12, 2025 | 8-K (2.02) | 0001193125-25-275889EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0000950170-25-106915EDGAR |
| May 6, 2025 | 8-K (2.02) | 0000950170-25-063959EDGAR |
| Mar 5, 2025 | 8-K (2.02) | 0000950170-25-033071EDGAR |
| Nov 12, 2024 | 8-K (2.02) | 0000950170-24-124558EDGAR |
Never miss a TCRX filing.
Get an email when TCRX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Oct 16, 2026Source: SEC EDGAR.